IP Library Granted Patent US 9,938,498
Granted Patent B2
US 9,938,498 · App. 14/399,371 · Granted Apr 10, 2018

Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells

Inventors: Kyung Mi Lee (Seoul, KR); Seon Ah Lim (Seoul, KR); Cassian Yee (Seoul, KR)
Assignee: NKMAX Co., Ltd.
C12N5/0646A61K35/17A61K2039/5158C12N2501/2302C12N2502/1114C12N2502/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,938,498
App. No.
14/399,371
Granted
Apr 10, 2018
Kind
B2
Abstract

The present invention relates to a method for inducing and expanding natural killer cells derived from peripheral blood mononuclear cells, which comprises co-culturing, as feeder cells, irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells in the presence of cytokines, along with peripheral blood mononuclear cells. According to the present invention, a large quantity of natural killer cells can be induced and proliferated from a small quantity of peripheral blood mononuclear cells even without the use of high-cost equipment or various kinds of expensive cytokines, thereby making it possible to significantly improve the efficiency and efficacy of the prevention and treatment of cancer using the natural killer cells.

Claims (5)

1. A method for inducing and expanding natural killer (NK) cells derived from peripheral blood mononuclear cells, wherein the method comprises co-culturing irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells as feeder cells with peripheral blood mononuclear cells in the presence of cytokines.

2. The method of claim 1 , wherein the peripheral blood mononuclear cells are obtained from a normal person or a cancer patient.

3. The method of claim 1 , wherein each of the irradiated Jurkat cells or the irradiated EBV-LCL cells is obtained by treatment with radiation of 100 to 500 Gy.

4. The method of claim 1 , wherein the cytokines are one or more selected from the group consisting of IL-2, IL-15, IL-21, Flt3-L, SCF, IL-7, IL-12, and IL18.

5. The method of claim 1 , wherein the method further comprises performing a subsequent culture to maintain the NK cells after inducement and proliferation of the NK cells derived from the peripheral blood mononuclear cells, wherein irradiated Jurkat cells, irradiated EBV-LCL cells and cytokines are added to the subsequent culture on the 1 st to the 15 th day of the subsequent culture.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2016
From: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
To: NKMAX CO., LTD.
Reel/Frame 039658/0601 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2016
From: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
To: NKMAX CO., LTD.
Reel/Frame 039109/0613 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2015
From: LEE, KYUNG MI; YEE, CASSIAN; LIM, SEON AH
To: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
Reel/Frame 035193/0729 →
Priority Claims (2)
KR 10-2012-0048165 · May 7, 2012 · national
KR 10-2013-0051442 · May 7, 2013 · national
Continuity (1)
Related Publication 20150152387A1 · Jun 4, 2015